716TiP IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy
| Autor: | Powles, T.B., Gschwend, J.E., Bracarda, S., Castellano, D., Gross-Goupil, M., Bjerggaard Jensen, J., Kann, A., Nishiyama, H., Makaroff, L., Lassidi, H., Mariathasan, S., Zhang, J., Degaonkar, V., Bellmunt, J. |
|---|---|
| Zdroj: | In Annals of Oncology September 2021 32 Supplement 5:S721-S721 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|